Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
22.80
+0.09 (0.40%)
At close: Jul 17, 2026, 4:00 PM EDT
22.50
-0.30 (-1.32%)
After-hours: Jul 17, 2026, 4:55 PM EDT
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 298 employees as of December 31, 2025. The number of employees increased by 28 or 10.37% compared to the previous year.
Employees
298
Change (1Y)
28
Growth (1Y)
10.37%
Revenue / Employee
$728,772
Profits / Employee
-$816,272
Market Cap
2.02B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 298 | 28 | 10.37% | 298 | 0 |
| Dec 31, 2024 | 270 | 86 | 46.74% | 270 | 0 |
| Dec 31, 2023 | 184 | 77 | 71.96% | 184 | 0 |
| Dec 31, 2022 | 107 | 48 | 81.36% | 107 | 0 |
| Dec 31, 2021 | 59 | 16 | 37.21% | 59 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| AbCellera Biologics | 562 |
| Lakefront Biotherapeutics NV | 558 |
| Ocular Therapeutix | 325 |
| Nuvation Bio | 307 |
| UroGen Pharma | 298 |
| Viridian Therapeutics | 252 |
| Monte Rosa Therapeutics | 187 |
SNDX News
- 5 days ago - Syndax Pharmaceuticals Transcript: R&D Day 2026 - Transcripts
- 5 days ago - Syndax Pharmaceuticals Slides: FY 2026 - Filings
- 5 days ago - Syndax Pharmaceuticals Press release: FY 2026 - Filings
- 5 days ago - Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event - GlobeNewsWire
- 17 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Syndax price target lowered to $31 from $34 at Guggenheim - TheFly
- 5 weeks ago - Syndax presents data from SAVE trial at EHA - TheFly
- 5 weeks ago - Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 - GlobeNewsWire